Close Menu

Precision Oncology News

A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.

The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.

The recommendation would make the cell therapy available to patients in the National Health Service, while NICE continues collecting long-term survival data.